RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma
- Scientists demonstrate the potential of improving therapy with patient-derived tumor infiltrating lymphocytes (TILs) by applying RXi's novel sd-rxRNA compounds specific to PD-1. Targeting the P...
Page (1) of 1 - 04/16/18||
(April 16, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved